Immune Modulation in Sepsis, ARDS, and Covid-19 - The Road Traveled and the Road Ahead

NEJM Evid. 2022 Nov;1(11):EVIDra2200118. doi: 10.1056/EVIDra2200118. Epub 2022 Oct 25.

Abstract

Immune Modulation in Sepsis, ARDS, and Covid-19Leligdowicz et al. consider the history and future of immunomodulating therapies in sepsis and ARDS, including ARDS due to Covid-19, and remark on the larger challenge of clinical research on therapies for syndromes with profound clinical and biologic heterogeneity.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Humans
  • Respiratory Distress Syndrome* / drug therapy
  • Sepsis*